Global Phenprocoumon Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Phenprocoumon Market Research Report 2024
Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting oral anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism).
According to Mr Accuracy reports’s new survey, global Phenprocoumon market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Phenprocoumon market research.
Key manufacturers engaged in the Phenprocoumon industry include Novartis, Mylan, Teva, Roche, Aspen Pharmacare, Acis Arzneimittel, Wörwag Pharma and Divis Labs, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Phenprocoumon were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Phenprocoumon market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Phenprocoumon market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis
Mylan
Teva
Roche
Aspen Pharmacare
Acis Arzneimittel
Wörwag Pharma
Divis Labs
Segment by Type
5 mg
10 mg
25 mg
50 mg
Venous Thrombosis
Thromboembolism
Pulmonary Embolism
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Phenprocoumon report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Phenprocoumon market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Phenprocoumon market research.
Key manufacturers engaged in the Phenprocoumon industry include Novartis, Mylan, Teva, Roche, Aspen Pharmacare, Acis Arzneimittel, Wörwag Pharma and Divis Labs, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Phenprocoumon were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Phenprocoumon market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Phenprocoumon market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Mylan
Teva
Roche
Aspen Pharmacare
Acis Arzneimittel
Wörwag Pharma
Divis Labs
Segment by Type
5 mg
10 mg
25 mg
50 mg
Segment by Application
Venous Thrombosis
Thromboembolism
Pulmonary Embolism
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Phenprocoumon report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source